Table 4 Percentage of individuals with a positive OV16 antibody test by age category, gender, health area, ivermectin use and diagnosis of epilepsy
Number of OV16+ | Number of OV16− | Percentage of OV16+ (95% CI) | |
|---|---|---|---|
Age groups | |||
0–9 | 12 | 265 | 4.3 (2.5–7.4) |
10–19 | 51 | 196 | 20.7 (16.1–26.1) |
20–29 | 52 | 62 | 45.6 (36.8–54.8) |
30–39 | 55 | 30 | 64.7 (54.1–74.0) |
40–49 | 46 | 33 | 58.2 (47.2–68.5) |
50+ | 62 | 48 | 56.4 (47.0–65.3) |
Gender | |||
Male | 125 | 305 | 29.1 (25.0–33.5) |
Female | 153 | 329 | 31.7 (27.8–36.0) |
Health area | |||
Draju | 155 | 278 | 35.8 (31.4–40.4) |
Kanga | 123 | 356 | 25.7 (22.0–29.8) |
Ivermectin use | |||
Yes | 18 | 13 | 58.1 (40.8–73.6) |
No | 260 | 621 | 29.5 (26.6–32.6) |
Epilepsy | |||
Yes | 25 | 29 | 46.3 (33.7–59.4) |
No | 253 | 605 | 29.5 (26.5–32.6) |